OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator. This document is also available as Markdown.

← Melanoma UK

2024-08-31-accounts

Company registration number: 8180701 Charity registration number: 1157635

Melanoma UK Limited

(A company limited by guarantee)

Annual Report and Financial Statements for the Year Ended 31 August 2024

Beever and Struthers One Express 1 George Leigh Street Manchester M4 5DL

Melanoma UK Limited

Contents

Reference and Administrative Details 1
Trustees' Report 2 to 6
Independent Examiner's Report 7
Statement of Financial Activities 8
Balance Sheet 9
Notes to the Financial Statements 10 to 20

Melanoma UK Limited

Reference and Administrative Details

Chief Executive Officer

Mark Rawden (ceased 31 October 2024)

Trustees David Bridge Adrian Carroll Paula Bridge Principal Office Adamson House The Towers Business Park Didsbury Manchester M20 2YY Registered Office C/o Beever and Struthers One Express 1 George Leigh Street Manchester M4 5DL Company Registration Number 8180701 Charity Registration Number 1157635 Independent Examiner Beever and Struthers One Express 1 George Leigh Street Manchester M4 5DL

Page 1

Melanoma UK Limited

Trustees' Report

The trustees present their annual report together with the financial statements of the Company for the year ended 31 August 2024. The annual report serves the purposes of both a Trustees' report and a directors' report under company law. The Trustees confirm that the annual report and financial statements of the charitable company comply with the current statutory requirements, the requirements of the charitable company's governing document and the provisions of the Statement of Recommended Practice (SORP) applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (second edition of the Charities SORP (FRS102) October 2019, effective 1 January 2019).

Since the Company qualifies as small under section 382 of the Companies Act 2006, the Strategic Report required of medium and large companies under the Companies Act 2006 (Strategic Report and Directors' Report) Regulations 2013 has been omitted.

Objectives and activities

In setting objectives and planning for activities, the Trustees have given due consideration to general guidance published by the Charity Commission relating to public benefit, including the guidance 'Public benefit: running a charity (PB2)'.

The objects of Melanoma UK Incorporating Factor 50 (hereinafter referred to as Melanoma UK) as set out in its Memorandum of Association are to:

  1. To provide patient support and assist in the awareness of the condition Malignant Melanoma.

  2. To provide funds for vital research with regards to the development of drugs to prolong and preserve quality of life.

  3. To educate and increase awareness of the dangers of Melanoma.

We have developed 2 vision/mission statements to help us remain focused within our activities.

Our Vision is to make a difference in the fight against melanoma by supporting advancements in prevention, treatment, and cure. By raising funds and awareness, we will help individuals to be proactive with early detection and provide information about diagnosis, treatment and support through their journey with Melanoma

Our Mission is to provide support, education, and advocacy for those directly and indirectly impacted by Melanoma, in collaboration and alignment with professionals working in the field of diagnosis, treatment and research. Our core focus is to help promote skin health by reducing the instances and impact of this largely avoidable skin cancer.

Strategic Objectives

Page 2

Melanoma UK Limited

Trustees' Report

Review of activities

From a modest level of fundraising activity at the end of 2023 we have worked hard to increase levels throughout 2024 and into 2025.

We had our very successful Beauty Spotters campaign which was launched in May 2024 where we focused on the beauty industry highlighting the risks of Acral melanoma within the Black and Brown communities. This got a lot of exposure from the main tabloids and magazines such as Cosmopolitan and Women’s Health

This was closely followed by the “1804 Garden”, the headlining show garden, which featured at RHS Tatton Garden show in July 2024 . The design by Carolyn Harden and Jon Jarvis won a silver award at the show for its intuitive design highlighting skin cancer and the link between physical and mental health. The Melanoma team were on hand every day to engage with the public offering advice on safe sun.

After Tatton a scaled down version was on show at the Southport flower show before being finally donated to Lancashire and South Cumbria NHS Foundation Trust to be used as a well being garden for mental health patients and NHS workers.

On the back of last years very successful awareness campaigns we have continued our partnership with Jewson Builder`s merchants, one of the largest builders merchants in the UK. We were invited to attend and provide speakers for numerous live events across the country.

We are delighted to confirm that we been able to place another Horus 800 mole mapping machine this time within the Norfolk and Norwich University Hospital which will enable them to supply to patients across the region and will help identify issues earlier and receive treatment sooner which will ultimately save lives. The machine was donated in memory of Neil Evans by the funds raised by his family and friends and we were delighted to meet his family for the unveiling of the plaque recognizing the donation in Neil`s memory.

We were delighted to see our Ambassador David Utterly scale the heights of Kilimanjaro for a second time in aid of Melanoma UK. David`s support with fundraising , giving talks and appearing on radio interviews has been amazing over the last year and is greatly appreciated by all.

We have worked closely with the team at Run for Charity and on the back of receiving more applications to support Melanoma UK have secured 5 places for the London Landmarks , 15 runners for the Hackney Half marathon and we are delighted to have secured a place in the London Marathon for 2025

The Charity`s lottery was relaunched as the “1804” ( recognizing the year Melanoma was first mentioned in medical journals ) and our general appeal for use of funds wherever the need is greatest along with individual fundraiser activity have positively impacted the charity funds.

Improved awareness is being pushed on several fronts via Website & SM activity, partnerships, connections with professional organisations, clinicians and now recently government (via MUK presence at a parliamentary round table in March which is expected to develop further). There has been some good work on education/ awareness materials and increased connections with other Charities.

Recently MUK joined One Cancer Voice via Cancer 52, calling on the UK government for more investment to fully fund the national Cancer Plan. This was shared across media.

Another positive development on this objective is recent invite and attendance of a Parliamentary roundtable on UV safety linked to Sunbeds. This is expected to develop into a joint campaign including respected representatives from across the Beauty industry and media. The potential outcomes of this could lead to better awareness and hopefully control and legislation (including Gov Health warnings at point of use).

Page 3

Melanoma UK Limited

Trustees' Report

Financial review

The charity's income is mainly from donations and discretionary sponsorship. Income for the year was £285,944 (2023: £455,227) with restricted income equating to £nil (2023 - £nil) and unrestricted to £285,944 (2023: £455,227).

At the end of the year there were total funds of £310,653 (2023: £265,822) comprising £4,562 (2023: £4,562) of restricted funds and £306,091 (2023: £261,260) of unrestricted funds.

Amounts held in fixed assets were £2,790 leaving £307,863 in free reserves.

Despite the difficulties experienced by the impact of Covid -19 and the current Public enquiry the Trustees have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future and are optimistic about its position going forward having secured new partnerships which will benefit the charity going forward.

We have improved control on spend with updated financial policies and tighter expenses management, unrequired services have been terminated and settlement of outstanding/ disputed charges have helped rationalize the accounting process leading to lower financial accounting and legal costs moving forward. Quarterly Financial updates are in place with our external accountants, including financial outlook benchmarking.

MUK has made solid progress across its strategic objectives, particularly in partnerships, fundraising structure, public awareness, and advocacy. Continued focus on corporate engagement, structured fundraising, and policy influence will be key to maintaining momentum.

With the evolution, stabilisation and development of the Charity, MUK is becoming better placed to engage with external organisations and progress is being made in this area. Connections with NHS parties, Cancer 52 and others have been remade and confidence is growing. With a larger, increasingly diverse and experienced Trustee team, coupled with renewed senior management and CEO leadership, MUK is becoming better placed to have a ‘voice at the table’ in Melanoma related matters.

Policy on reserves

The Trustees aim to maintain reserves in unrestricted funds at a desired level of £100,000, This level of reserves is considered to be reasonable to support the charity's ongoing commitments.

At the financial year end, Melanoma UK’s reserves were higher than the stated reserves policy of £100,000.

Plans for future periods

Aims and key objectives for future periods

The current Trustees intend to expand the board of Trustees to add specific skill sets, to increase Trustee involvement and supervision who will compliment the scheme of delegation which has been devised. The fundamentals of the Charity will be maintained and strengthened. The Charity will continue to reduced expense levels by moving to a virtual platform following the closure of the physical office which will enable it to devote more time and funds to the charitable aims. The charity has a wealth of support and a genuine reason to thrive.

Going concern

The Trustees have a reasonable expectation that the Charity has adequate resources to continue in operational existence for the foreseeable future.

Page 4

Melanoma UK Limited

Trustees' Report

Structure, governance and management

Melanoma UK is registered as a charitable company limited by guarantee and was set up by a Memorandum of Association on 15/08/2012, and the Articles were since amended by a special resolution passed on 27/05/2014 with charity registration number 1157635.

Recruitment and appointment of trustees

The company is the responsibility of the trustees who are elected in accordance with the terms in its Memorandum of Association. The Trustees are legally responsible for managing, controlling, and directing the affairs of their charity. All directors of the company are also trustees of the charity, and there are no other trustees. The trustees named below served in the year. The board has the power to appoint additional trustees as it considers fit to do so based on their suitability for the role. A board skills audit was undertaken with a view to expand the skillset of the board and recruitment is ongoing.

The Trustees who served during the year were: -

Mrs Paula Bridge Mr David Bridge Mr Adrian Carroll

Organisational structure

People support has improved with the full time Administration role ensuring timely responses to enquiries (including signposting) as well as consistent support and thank you communications for donations and fundraisers. Lindsey Brough is assisted by Deborah Thomassen who continues in a part-time capacity to lend support and HR guidance.

We bid farewell to our interim CEO Mark Rawden and welcomed our new permanent CEO Tracy Paine MBE who has a wealth of experience in the charity sector. She is ably assisted in the management of the Charity by Colin Glover our COO who has had a huge impact on the internal functions and governance within the Charity.

Page 5

Melanoma UK Limited

Trustees' Report

Statement of Trustees' Responsibilities

The trustees (who are also the directors of Melanoma UK Limited for the purposes of company law) are responsible for preparing the trustees' report and the financial statements in accordance with the United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) and applicable law and regulations.

Company law requires the trustees to prepare financial statements for each financial year. Under company law the trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the trustees are required to:

The trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charitable company's transactions and disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

17/04/25 The annual report was approved by the trustees of the charity on .................... and signed on its behalf by:

......................................... David Bridge Trustee

Page 6

Melanoma UK Limited

Independent Examiner's Report to the trustees of Melanoma UK Limited

I report on the accounts of the charity for the year ended 31 August 2024 which are set out on pages 8 to 20 .

Respective responsibilities of trustees and examiner

The trustees (who are also the directors of the company for the purposes of company law) are responsible for the preparation of the accounts. The trustees consider that an audit is not required for this year under section 144(2) of the Charities Act 2011 (the 2011 Act) and that an independent examination is needed. The charity's gross income exceeded £250,000 and I am qualified to undertake the examination by being a qualified member of ICAEW .

Having satisfied myself that the charity is not subject to audit under company law and is eligible for independent examination, it is my responsibility to:

Basis of independent examiner’s report

My examination was carried out in accordance with the general Directions given by the Charity Commission. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts, and seeking explanations from you as trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit and consequently no opinion is given as to whether the accounts present a ‘true and fair view’ and the report is limited to those matters set out in the statement below.

Independent examiner's statement

In connection with my examination, no matter has come to my attention:

have not been met; or

......................................

Helen Binns FCA ICAEW

One Express 1 George Leigh Street Manchester M4 5DL

Date:............................. 17 April 2025

Page 7

Melanoma UK Limited

Statement of Financial Activities for the Year Ended 31 August 2024 (Including Income and Expenditure Account and Statement of Total Recognised Gains and Losses)

Note
Income and Endowments from:
Donations and legacies
3
Other trading activities
4
Investment income
5
Total Income
Expenditure on:
Charitable activities
6
Total Expenditure
Net income
Net movement in funds
Reconciliation of funds
Total funds brought forward
Total funds carried forward
16
Note
Income and Endowments from:
Donations and legacies
3
Other trading activities
4
Investment income
5
Total Income
Expenditure on:
Charitable activities
6
Total Expenditure
Net expenditure
Transfers between funds
Net movement in funds
Reconciliation of funds
Total funds brought forward
Total funds carried forward
16		 Unrestricted
funds
£
267,102
11,489
7,353
285,944
241,113
241,113
44,831
44,831
261,260
306,091
Unrestricted
funds
£
418,837
30,661
5,729
455,227
557,274
557,274
(102,047)
40,050
(61,997)
323,257
261,260		 Restricted
funds
£
-
-
-
-
-
-
-
-
4,562
4,562
Restricted
funds
£
-
-
-
-
-
-
-
(40,050)
(40,050)
44,612
4,562		 Total
2024
£
267,102
11,489
7,353
285,944
241,113
241,113
44,831
44,831
265,822
310,653
Total
2023
£
418,837
30,661
5,729
455,227
557,274
557,274
(102,047)
-
(102,047)
367,869
265,822

All of the charity's activities derive from continuing operations during the above two periods. The funds breakdown for 2023 is shown in note 16.

Page 8

Melanoma UK Limited

(Registration number: 8180701) Balance Sheet as at 31 August 2024

2024 2023
Note £ £
Fixed assets
Tangible assets 12 2,790 29,865
Current assets
Stocks 13 8,985 -
Debtors 14 70,549 77,746
Cash at bank and in hand 260,074 426,558
339,608 504,304
Creditors: Amounts falling due within one year 15 (31,745) (268,347)
Net current assets 307,863 235,957
Net assets 310,653 265,822
Funds of the charity:
Restricted funds 4,562 4,562
Unrestricted income funds
Unrestricted funds 306,091 261,260
Total funds 16 310,653 265,822

For the financial year ending 31 August 2024 the charity was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements on pages 8 to 20 were approved by the trustees, and authorised for issue on 17.04.25 .................... and signed on their behalf by:

......................................... David Bridge Trustee

Page 9

Melanoma UK Limited

Notes to the Financial Statements for the Year Ended 31 August 2024

1 Charity status

The charity is a charity limited by guarantee and consequently does not have share capital. Each of the trustees is liable to contribute an amount not exceeding £10 towards the assets of the charity in the event of liquidation.

2 Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

Basis of preparation

Melanoma UK Limited meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

Going concern

The trustees consider that there are no material uncertainties about the charity's ability to continue as a going concern nor any significant areas of uncertainty that affect the carrying value of assets held by the charity.

Exemption from preparing a cash flow statement

The charity opted to early adopt Bulletin 1 published on 2 February 2016 and have therefore not included a cash flow statement in these financial statements.

Income and endowments

All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of the income receivable can be measured reliably.

Donations and legacies

Donations are recognised when the charity has been notified in writing of both the amount and settlement date. In the event that a donation is subject to conditions that require a level of performance by the charity before the charity is entitled to the funds, the income is deferred and not recognised until either those conditions are fully met, or the fulfilment of those conditions is wholly within the control of the charity and it is probable that these conditions will be fulfilled in the reporting period.

Page 10

Melanoma UK Limited

Notes to the Financial Statements for the Year Ended 31 August 2024

Investment income

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the bank. Dividends are recognised once the dividend has been declared and notification has been received of the dividend due.

Expenditure

All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a basis consistent with the use of resources, with central staff costs allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset’s use. Other support costs are allocated based on the spread of staff costs.

Charitable activities

Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Support costs

Support costs include central functions and have been allocated to activity cost categories on a basis consistent with the use of resources, for example, allocating property costs by floor areas, or per capita, staff costs by the time spent and other costs by their usage.

Governance costs

These include the costs attributable to the charity’s compliance with constitutional and statutory requirements, including audit, strategic management and trustees’ meetings and reimbursed expenses.

Taxation

The charity is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.

Tangible fixed assets

Individual fixed assets are initially recorded at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

Depreciation and amortisation

Depreciation is provided on tangible fixed assets so as to write off the cost or valuation, less any estimated residual value, over their expected useful economic life as follows:

Asset class Depreciation method and rate
Motor vehicles 25% reducing balance
Fixtures, fittings and equipment 20% straight line
Office equipment 20% straight line

Page 11

Melanoma UK Limited

Notes to the Financial Statements for the Year Ended 31 August 2024

Stock

Stock is valued at the lower of cost and estimated selling price less costs to complete and sell, after due regard for obsolete and slow moving stocks. Cost is determined using the first-in, first-out (FIFO).

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the charity does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Fund structure

Unrestricted income funds are general funds that are available for use at the trustees's discretion in furtherance of the objectives of the charity.

Designated funds are unrestricted funds earmarked by the trustees for particular future project or commitment.

Restricted income funds are those donated for use in a particular area or for specific purposes, the use of which is restricted to that area or purpose.

Financial instruments

Classification

Financial assets and financial liabilities are recognised when the charity becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the charity after deducting all of its liabilities.

Page 12

Melanoma UK Limited

Notes to the Financial Statements for the Year Ended 31 August 2024

Recognition and measurement

All financial assets and liabilities are initially measured at transaction price (including transaction costs), except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value (which is normally the transaction price excluding transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a financing transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Financial assets and liabilities are only offset in the statement of financial position when, and only when there exists a legally enforceable right to set off the recognised amounts and the charity intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Financial assets are derecognised when and only when a) the contractual rights to the cash flows from the financial asset expire or are settled, b) the charity transfers to another party substantially all of the risks and rewards of ownership of the financial asset, or c) the charity, despite having retained some, but not all, significant risks and rewards of ownership, has transferred control of the asset to another party.

Financial liabilities are derecognised only when the obligation specified in the contract is discharged, cancelled or expires.

3 Income from donations and legacies

Donations and legacies;
Donations from individuals
Gift aid reclaimed		 Unrestricted
funds
General
£
256,690
10,412
267,102		 Total
2024
£
256,690
10,412
267,102		 Total
2023
£
358,700
60,137
418,837

4 Income from other trading activities

Trading income;
Shop income from sale of donated goods and services
Lotteries and competitions income		 Unrestricted
funds
General
£
-
11,489
11,489		 Total
2024
£
-
11,489
11,489		 Total
2023
£
11,208
19,453
30,661

Page 13

Melanoma UK Limited

Notes to the Financial Statements for the Year Ended 31 August 2024

5 Investment income

Interest receivable and similar income;
Other interest receivable		 Unrestricted
funds
General
£
7,353		 Total
2024
£
7,353		 Total
2023
£
5,729

Page 14

Melanoma UK Limited

Notes to the Financial Statements for the Year Ended 31 August 2024

6 Expenditure on charitable activities

Note
Staff costs
9
Allocated support costs
Governance costs
7
Fundraising costs
Advertising and marketing
Direct expenditure
Premises costs
Insurance
Finance costs
Motor and travel
Consulting
Entertainment
Staff costs
Staff training
Hire of equipment
Depreciation
Profit on disposal of fixed asset
Website and social media costs
Telephone and internet
Sundry
Interest payable
Event costs
Provision of medical equipment
Legal and professional
Exceptional admin costs
Printing, postage and stationery
Office expenses
Governance		 Unrestricted
funds
General
£
22,882
204,291
13,940
241,113
Activity
support costs
£
3,963
9,019
(8,985)
1,808
1,426
1,162
2,173
96,254
73
22,883
-
457
2,698
(2,833)
16,328
7,305
6,536
-
-
-
2,173
62,638
1,463
632
13,940
241,113		 Total
2024
£
22,882
204,291
13,940
241,113
Total
2024
£
3,963
9,019
(8,985)
1,808
1,426
1,162
2,173
96,254
73
22,883
-
457
2,698
(2,833)
16,328
7,305
6,536
-
-
-
2,173
62,638
1,463
632
13,940
241,113		 Total
2023
£
143,597
408,943
4,734
557,274
Total
2023
£
13,315
8,219
14,118
13,265
1,693
1,336
3,443
36,954
-
143,597
3,500
658
9,955
-
12,897
6,008
1,938
3,163
33,000
118,233
30,312
96,936
-
-
4,734
557,274

£241,113 (2023 - £557,274) of the above expenditure was attributable to unrestricted funds and £Nil (2023 - £Nil) to restricted funds.

Page 15

Melanoma UK Limited

Notes to the Financial Statements for the Year Ended 31 August 2024

7 Analysis of governance and support costs

Governance costs

Independent examiner fees
Examination of the financial statements
Other fees paid to examiners		 Unrestricted
funds
General
£
3,300
10,640
13,940		 Total
2024
£
3,300
10,640
13,940		 Total
2023
£
3,300
1,434
4,734

8 Trustees remuneration and expenses

During the year the charity made the following transactions with trustees:

Gillian Nuttall

Gillian Nuttall received remuneration of £8,370 (2023: £68,480) during the year.

At the year end there was an amount due from Gillian Nuttall, a former trustee, of £17,776 (2023: £17,610). As this is unlikely to be recoverable, for accounting purposes this amount has been written off to exceptional administration expenses.

9 Staff costs

The aggregate payroll costs were as follows:

Staff costs during the year were:
Wages and salaries
Social security costs
Pension costs
Other staff costs		 2024
£
22,508
-
374
-
22,882		 2023
£
103,665
36,201
1,931
1,800
143,597

The monthly average number of persons (including senior management team) employed by the charity during the year expressed as full time equivalents was as follows:

Average number of employees including directors 2024
No
-		 2023
No
6

The number of employees whose emoluments fell within the following bands was:

Page 16

Melanoma UK Limited

Notes to the Financial Statements for the Year Ended 31 August 2024

2023 No £60,001 - £70,000 1

The total employee benefits of the key management personnel of the charity were £Nil (2023 - £12,650).

10 Independent examiner's remuneration

10 Independent examiner's remuneration
Examination of the financial statements
Other fees to examiners
All other services		 2024
£
3,300
10,640		 2023
£
3,300
1,434

Page 17

Melanoma UK Limited

Notes to the Financial Statements for the Year Ended 31 August 2024

11 Taxation

The charity is a registered charity and is exempt from taxation of its income and gains falling within section 524 of the Income Tax Act 2007 to the extent that they are applied to its charitable objectives. No tax charge has arisen in the current and prior year.

12 Tangible fixed assets

Cost
At 1 September 2023
Additions
Disposals
At 31 August 2024
Depreciation
At 1 September 2023
Charge for the year
Eliminated on disposals
At 31 August 2024
Net book value
At 31 August 2024
At 31 August 2023
13 Stock
Stocks
14 Debtors
Accrued income
Other debtors		 Furniture and
equipment
£
6,268
2,790
(5,888)
3,170
6,040
228
(5,888)
380
2,790
228		 Furniture and
equipment
£
6,268
2,790
(5,888)
3,170
6,040
228
(5,888)
380
2,790
228		 Motor
vehicles
£
52,688
-
(52,688)
-
23,051
2,470
(25,521)
-
-
29,637
2024
£
70,549
-
70,549		 Motor
vehicles
£
52,688
-
(52,688)
-
23,051
2,470
(25,521)
-
-
29,637
2024
£
70,549
-
70,549		 Total
£
58,956
2,790
(58,576)
3,170
29,091
2,698
(31,409)
380
2,790
29,865
2024
£
8,985
380 -
2,790 -
228 29,637
2024
£
70,549
-
70,549
2023
£
60,137
17,609
77,746

Page 18

Melanoma UK Limited

Notes to the Financial Statements for the Year Ended 31 August 2024

15 Creditors: amounts falling due within one year

Trade creditors
Other taxation and social security
Other creditors
Accruals
16 Funds
Unrestricted funds
General
General
Restricted funds
Non Melanoma Skin Cancer
B-raf Awareness
Total restricted funds
Total funds
Unrestricted funds
General
General
Restricted funds
Mole Hunt
Non Melanoma Skin Cancer
B-raf Awareness
Total restricted funds
Total funds		 2024
£
(As restated)
2023
£
25,752
74,243
(947)
82,341
-
4,393
6,940
107,370
31,745
268,347
Balance at 1
September
2023
£
Incoming
resources
£
Resources
expended
£
Balance at 31
August 2024
£
261,260
285,944
(241,113)
306,091
1,000
-
-
1,000
3,562
-
-
3,562
4,562
-
-
4,562
265,822
285,944
(241,113)
310,653
Balance at 1
September
2022
£
Incoming
resources
£
Resources
expended
£
Transfers
£
Balance at
31 August
2023
£
323,257
455,227
(557,274)
40,050
261,260
40,050
-
-
(40,050)
-
1,000
-
-
-
1,000
3,562
-
-
-
3,562
44,612
-
-
(40,050)
4,562
367,869
455,227
(557,274)
-
265,822		 (As restated)
2023
£
74,243
82,341
4,393
107,370		 (As restated)
2023
£
74,243
82,341
4,393
107,370
268,347
Balance at 31
August 2024
£
306,091
1,000
3,562
4,562
310,653
Balance at
31 August
2023
£
261,260
-
1,000
3,562
4,562
265,822

Page 19

Melanoma UK Limited

Notes to the Financial Statements for the Year Ended 31 August 2024

17 Analysis of net assets between funds

17 Analysis of net assets between funds
Tangible fixed assets
Current assets
Current liabilities
Total net assets		 Unrestricted
funds
General
£
2,790
324,634
(31,745)
295,679		 Restricted
funds
£
-
4,562
-
4,562		 Total funds
£
2,790
329,196
(31,745)
300,241

Page 20